High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Psychotropic drugs are used for treatment of behavioral and psychological symptoms of dementia (BPSD) although they are associated with serious adverse drug events. Objective of our study was to investigate prevalence of psychotropic drug use one year after diagnoses of Alzheimer's disease (AD), to compare prevalence to persons without AD and to assess changes in prevalence over time. Data from the MEDALZ (Medication use and Alzheimer's disease) cohort was utilized in the study including all 69,080 community-dwelling persons with new diagnosis of AD during years 2005-2011 in Finland. Four age-, gender- and region of residence-matched persons without AD were identified for each case. Register-based data included prescription drug purchases and comorbidities from Special Reimbursement Register. Annual prevalence of psychotropic drug use one year after diagnosis was determined for each person. Psychotropic drugs were used by 53% of persons with AD compared with 33% of persons without AD during one year after diagnoses. Persons with AD were six times more likely to use antipsychotics and three times more likely to use antidepressants whereas benzodiazepine and related drug (BZDR) use was comparable between persons with and without AD. According to year of AD diagnoses during 2005-2011, antipsychotic use increased from 18% to 20% (p<0.0001) and BZDR use declined from 31% to 26% (p<0.0001) among persons with AD. Widespread utilization of psychotropic drugs was observed among persons with AD. Despite safety warnings of antipsychotic use for BPSD, antipsychotic use increased from 2005 to 2011 among newly diagnosed persons with AD in Finland.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 1×
“Numerous studies indicate the association between antipsychotic use and an increased mortality risk (Schneider et al., 2005; Wang et al., 2005; Schneeweiss et al., 2007; Ballard et al., 2009; Kales et al., 2012; Gerhard et al., 2014) with some conflicting results (Gardette et al., 2012; Lopez et…”
Antidepressant use and risk of adverse outcomes in older people: population based cohort study
Coupland, C., Dhiman, P., Morriss, R., Arthur, A., Barton, G., & Hippisley-Cox, J. (2011) · BMJ · doi:10.1136/bmj.d4551 · Cited by 833 · cited 3×
“All psychotropic drugs have been associated with falls and hip fractures (Cumming and Le Couteur, 2003; Hartikainen et al., 2007; Coupland et al., 2011; Oderda et al., 2012; Xing et al., 2014).”
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Risk of Mortality Among Individual Antipsychotics in Patients With Dementia
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., Seyfried, L. S., Chiang, C., Cunningham, F., Schneider, L. S., & Blow, F. C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11030347 · Cited by 384
Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061250 · Cited by 366
Lopez, O. L., Becker, J. T., Chang, Y.-F., Sweet, R. A., Aizenstein, H., Snitz, B., Saxton, J., McDade, E., Kamboh, M. I., DeKosky, S. T., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12081046 · Cited by 129 · cited 3×
“, 2009) whereas other studies have not verified the risk in long-term use (Gardette et al., 2012; Lopez et al., 2013).”
Oderda, L. H., Young, J. R., Asche, C. V., & Pepper, G. A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q589 · Cited by 94 · cited 1×
“All psychotropic drugs have been associated with falls and hip fractures (Cumming and Le Couteur, 2003; Hartikainen et al., 2007; Coupland et al., 2011; Oderda et al., 2012; Xing et al., 2014).”
Cited by
International trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuoliené, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 282
Ralph, S. J., & Espinet, A. J. (2018) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170042 · Cited by 160
“Despite the extensive evidence that these drugs increase all-cause mortality in dementia and other patients, they remain commonly overprescribed and in some countries have seen little to no change in use or in many cases have been increasingly prescribed over the past 10 years, even for long term use and regardless of…”
BackgroundLornstad, M. T., Aarøen, M., Bergh, S., Benth, J. Š., & Helvik, A.-S. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1126-y · Cited by 24
Pirker-Kees, A., Dal-Bianco, P., & Schmidt, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181102 · Cited by 17
Metadata
- Authors
- Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A.-M., Tiihonen, J., & Hartikainen, S.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 24
- Issue
- 11
- Pages
- 1729-1737
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2049268457
- Cited by
- 73
- References
- 8
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort. https://app.cochat.ai/papers/10.1016/j.euroneuro.2014.10.004
- The paper
- Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A.-M., Tiihonen, J., & Hartikainen, S. (2014). High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2014.10.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.